|
1
|
Tate MC and Aghi MK: Biology of
angiogenesis and invasion in glioma. Neurotherapeutics. 6:447–457.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grauer OM, Wesseling P and Adema GJ:
Immunotherapy of diffuse gliomas: Biological background, current
status and future developments. Brain Pathol. 19:674–693. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Erickson LC, Bradley MO, Ducore JM, Ewig
RA and Kohn KW: DNA crosslinking and cytotoxicity in normal and
transformed human cells treated with antitumor nitrosoureas. Proc
Natl Acad Sci USA. 77:pp. 467–471. 1980; View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pegg AE, Dolan ME and Moschel RC:
Structure, function, and inhibition of O6-alkylguanine-DNA
alkyltransferase. Prog Nucleic Acid Res Mol Biol. 51:167–223. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen L, Han L, Shi Z, Zhang K, Liu Y,
Zheng Y, Jiang T, Pu P, Jiang C and Kang C: LY294002 enhances
cytotoxicity of temozolomide in glioma by down-regulation of the
PI3K/Akt pathway. Mol Med Rep. 5:575–579. 2012.PubMed/NCBI
|
|
6
|
Rodon J, Braña I, Siu LL, De Jonge MJ,
Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, et
al: Phase I dose-escalation and -expansion study of buparlisib
(BKM120), an oral pan-Class I PI3K inhibitor, in patients with
advanced solid tumors. Invest New Drugs. 32:670–681. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Butowski NA, Sneed PK and Chang SM:
Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin
Oncol. 24:1273–1280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sarkaria JN, Kitange GJ, James CD, Plummer
R, Calvert H, Weller M and Wick W: Mechanisms of chemoresistance to
alkylating agents in malignant glioma. Clin Cancer Res.
14:2900–2908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brandes AA, Franceschi E, Tosoni A, Blatt
V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F,
Andreoli A, et al: MGMT promoter methylation status can predict the
incidence and outcome of pseudoprogression after concomitant
radiochemotherapy in newly diagnosed glioblastoma patients. J Clin
Oncol. 26:2192–2197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Turriziani M, Caporaso P, Bonmassar L,
Buccisano F, Amadori S, Venditti A, Cantonetti M, D'Atri S and
Bonmassar E: O6-(4-bromothenyl) guanine (PaTrin-2), a novel
inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the
inhibitory activity of temozolomide against human acute leukaemia
cells in vitro. Pharmacol Res. 53:317–323. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Quinn JA, Jiang SX, Reardon DA, Desjardins
A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD,
Sampson JH, et al: Phase II trial of temozolomide plus
o6-benzylguanine in adults with recurrent, temozolomide-resistant
malignant glioma. J Clin Oncol. 27:1262–1267. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chakravarti A, Zhai G, Suzuki Y, Sarkesh
S, Black PM, Muzikansky A and Loeffler JS: The prognostic
significance of phosphatidylinositol 3-kinase pathway activation in
human gliomas. J Clin Oncol. 22:1926–1933. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Misra UK, Deedwania R and Pizzo SV:
Activation and cross-talk between Akt, NF-kappaB, and unfolded
protein response signaling in 1-LN prostate cancer cells consequent
to ligation of cell surface-associated GRP78. J Biol Chem.
281:13694–13707. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kumar A, Takada Y, Boriek AM and Aggarwal
BB: Nuclear factor-kappaB: Its role in health and disease. J Mol
Med (Berl). 82:434–448. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Senftleben U, Cao Y, Xiao G, Greten FR,
Krähn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC and Karin M:
Activation by IKKalpha of a second, evolutionary conserved,
NF-kappa B signaling pathway. Science. 293:1495–1499. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lavon I, Fuchs D, Zrihan D, Efroni G,
Zelikovitch B, Fellig Y and Siegal T: Novel mechanism whereby
nuclear factor kappaB mediates DNA damage repair through regulation
of O(6)-methylguanine-DNA-methyltransferase. Cancer Res.
67:8952–8959. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang H, Lin H, Zhang X and Li J:
Resveratrol reverses temozolomide resistance by downregulation of
MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
Oncol Rep. 27:2050–2056. 2012.PubMed/NCBI
|
|
20
|
Igney FH and Krammer PH: Death and
anti-death: Tumour resistance to apoptosis. Nat Rev Cancer.
2:277–288. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roos WP, Batista LF, Naumann SC, Wick W,
Weller M, Menck CF and Kaina B: Apoptosis in malignant glioma cells
triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
